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ABSTRACT We have identified a factor present in nuclear
extracts of undifferentiated F9 murine embryonal carcinoma
cells that specifically interacts with the polyomavirus enhancer
region. Nuclease "footprint" analysis was used to define the
binding site that corresponds precisely to the boundaries of
polyoma enhancer element C defined by Veldman et al.
[Veldman, G. M., Lupton, S. & Kamen, R. (1985) Mol. CeU.
Biol. 5, 649-658] that is required as an enhancer for efficient
viral DNA replication and early and late region transcription.
The region of nuclease protection contains a 6-base-pair
inverted repeat, separated by 3 base pairs, and symmetrical
flanking DNase I hypersensitive cleavage sites, suggesting that
this factor may bind as a dimer. A cloned 29-base-pair polyoma
DNA fragment contains an intact binding domain. Similar
levels of binding activity were found in nuclear extracts
prepared from differentiated murine F9 cells, as well as murine
L cells and human HeLa cells. The factor has been termed
"EF-C" for enhancer binding factor to polyoma element C.
Eukaryotic enhancer sequences regulate a variety ofviral and
cellular genes (reviewed in refs. 1 and 2). By definition,
enhancers activate transcription of a gene linked in cis in a
relatively orientation- and location-independent fashion. En-
hancer elements have been shown to display tissue and
species specificity and to activate transcription over large
distances (1, 2). Although the mechanism(s) of enhancer
function is unclear, these sequences have been shown to bind
trans-acting cellular factors (3-5).
We are interested in host factors that bind to the murine
polyomavirus enhancer region. The polyoma enhancer is
particularly interesting because this region regulates viral
expression in a developmentally specific fashion (see ref. 6
for a review) and also is required for efficient viral DNA
replication (7). deVilliers and Schaffner (8) originally identi-
fied an enhancer located in the noncoding sequences of the
polyoma genome [nucleotides (nt) 5021-5262, Fig. 1]. This
region has an altered chromatin structure (17) and contains
control elements for the early and late transcription units and
the origin of DNA replication (refs. 7, 8, and 17-22; Fig. 1).
Genetic analyses have demonstrated that the organization of
the polyoma enhancer is complex and functionally redundant
(although not sequence redundant). At least five separate
domains appear to contribute to the enhancer function of this
region (regions A-E, Fig. 1; refs. 7 and 14-16; also see ref.
6 for a review). The multiple nature and functional redun-
dance of the polyoma enhancer sequences may reflect a
capability to utilize a variety of cellular factors to obtain
optimal enhancer activity.
Polyomavirus lytic growth is restricted in a number of
undifferentiated mouse cell lines that include the embryonal
carcinoma lines F9 and PCC-4 as well as trophoblast and
neuroblastoma cell lines. Polyoma host range mutants adapt-
ed for growth in these undifferentiated cells contain complex
point and deletion mutations, duplications, and rearrange-
ments in the enhancer region (reviewed in ref. 6). The genetic
alterations in these mutants confirm the importance of the
enhancer regions discussed above (regions A-E, Fig. 1). Our
studies have focused on the enhancer region ofwild-type (wt)
polyoma and one prototypic F9 host range mutant (hrN2; ref.
23). Utilizing a sensitive filter binding assay to detect
DNA-protein complexes (24), we have identified a factor
present in undifferentiated F9 cell nuclear extracts that binds
both wt and hrN2 enhancer regions. This factor also was
found in nuclear extracts from differentiated F9 cells, murine
L cells, and human HeLa cells. Nuclease protection exper-
iments showed that this factor binds precisely within the
boundaries of enhancer element C (Fig. 1).
METHODS
Preparation of Nuclear Extract. Isolated nuclei (25) were
washed in lysis buffer minus Nonidet P-40, and nuclear
proteins were extracted using 0.3 M NaCl as described (26)
with the exception that the 0.1 M NaCl wash was omitted.
Extracts were dialyzed for 4 hr at 40C against 20 mM
Tris'HCl, pH 7.4/50 mM NaCl/25% (vol/vol) glycerol/0.1
mM EGTA/0.1 mM EDTA/0.5 mM dithiothreitol/phenyl-
methylsulfonyl fluoride at 85 pg/ml and stored in liquid
nitrogen. Protein concentrations were determined by the
method of Bradford (27).
Plasmids and Preparation of Labeled DNA. The Pvu II
fragment 4 (nt 5128-5262) from wt Toronto strain [134 base
pairs (bp)] or mutant hrN2 (167 bp; ref. 23) was inserted into
the Sma I site of the vector pUC9. Cloned fragments were
labeled at the EcoRI site in the pUC9 polylinker region using
Klenow polymerase and [a-32P]dATP (3000 Ci/mmol; 1 Ci =
37 GBq), excised from the plasmids by digestion with
BamHI, and purified by electrophoresis. Specific activities of
approximately 7.5 x 107 cpm/,ug of DNA were obtained.
Nonspecific DNAs for binding studies were the pBR322
EcoRI-EcoRV fragment (185 bp) and a pool of Hpa II
fragments of equivalent size labeled in the same fashion.
Plasmid pUC-EFC (containing a minimal binding domain)
was constructed by inserting an Xho I linker at the Hae III
site at polyoma nt 5174 in a pUC clone containing the hrN2
Pvu II fragment 4. The plasmid was linearized adjacent to the
Pvu II site at polyoma nt 5128, digested briefly with exonu-
clease III and then with S1 nuclease, repaired using Klenow
polymerase, and Bcl I linkers were added. The DNA was
digested with Bcl I and Xho I, and fragments containing the
binding site for the enhancer binding factor to polyoma
element C (EF-C) were inserted in pUC9 via the BamHI and
Abbreviations: bp, base pair(s); wt, wild type; nt, nucleotide(s);
EF-C, enhancer binding factor to polyoma element C.
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FIG. 1. A schematic drawing of the control region of polyomavirus. Nucleotide numbers of the sequenced polyoma A2 strain (9) are shown.
The sequence of the polyoma A2 strain in this region is very similar to the Toronto strain used in these studies with the exception of several
nucleotide changes (P.O. and P.H., unpublished data) and a duplication of nt 5096-5139 (10). Late and early region transcripts are indicated
by open boxes and arrows. Ori, minimal origin of replication. Homologies to other viral enhancer regions are indicated: ElA, adenovirus ElA
enhancer homology (11); SV40, homology with the simian virus 40 (SV40) core enhancer element (12); BPV, bovine papilloma virus enhancer
homology (13). EF-C is the region of nuclease protection described in this report, and the arrows indicate repeated sequences in this element.
C, single copy ofthe repeat in the EF-C binding domain; TATA, TATA box promoter homology. A, B, C, and D indicate elements of the polyoma
enhancer defined by Veldman et al. (14). Region E corresponds to an additional enhancer region generated in polyoma F9 host range mutants
(15, 16).
Sma I (converted to Xho I via a linker) sites. The clone
displayed in Fig. 5 (pUC-EFC) was selected for these studies.
Filter Binding Assay and DNase I "Footprint" Analysis. The
filter binding assays (50 1.d, final reaction volume) were
performed according to the procedure of Diffley and Stillman
(24). Various concentrations of the competitor DNA [poly-
(dA).oligo(dT)/poly(dC)-oligo(dG) homopolymer mix] were
incubated with nuclear extract in 25 mM Hepes-KOH, pH
7.4/5 mM MgCl/2 mM dithiothreitol/bovine serum albumin
at 50 Ag/ml/50 mM KCl for 15 min at room temperature.
32P-labeled DNA was added (2500-6000 cpm corresponding
to 33-80 pg of DNA), and the reaction was continued for 30
min at room temperature. Reactions were slowly filtered
through nitrocellulose using a Schleicher & Schuell manifold.
The filter was washed three times with 0.25 ml of ice cold 25
mM Hepes-KOH, pH 7.4/5 mM MgCl; and either the filter
was exposed to x-ray film, or the radioactivity in the dots was
measured directly by liquid scintillation counting.
Binding reactions for DNase I footprint analysis were
scaled up 5-fold. Following the binding reaction, 12 ,Al of
DNase I (Worthington; concentrations are in the figure
legends) in 25 mM Hepes-KOH, pH 7.5/100 mM MgCl2 and
50 mM CaCl2 were added, and the reaction mixtures were
incubated for 5 min at room temperature. DNase I concen-
trations that yielded single hit kinetics were determined
empirically. Reactions were terminated by the addition of 250
,ul of 100 mM Tris HCl, pH 8.0/20 mM EDTA/0.5% NaDod-
S04/0.15 M NaCl/tRNA at 50 ,g/ml, followed by extraction
with phenol/chloroform (1:1, vol/vol), chloroform, and sub-
sequent ethanol precipitation. Samples were electrophoresed
in 8% polyacrylamide/urea denaturing gels. Marker sequenc-
ing ladders were generated using homologous fragments by
the procedure of Maxam and Gilbert (28).
Cell Culture. F9 thymidine kinase deficient (F9 tk-) em-
bryonal carcinoma cells (29), kindly provided by Barbara
Knowles (Wistar Institute, Philadelphia) were plated on
gelatin-coated dishes in Delbecco's modified Eagle's medium
(DMEM) containing 10% (vol/vol) fetal bovine serum. F9
cells were stimulated to differentiate with 50 nM retinoic acid
and 0.1 mM dibutyrl cyclic AMP as described (30) and were
harvested 3-4 days later. Differentiation was monitored
visually and by assaying plasminogen activator activity (30).
HeLa cells were cultured in suspension in the suspension
formulation of Eagle's modified essential medium (SMEM)
containing 7% (vol/vol) calf serum, and L cells were grown
on dishes in DMEM containing 10% (vol/vol) calf serum.
RESULTS
A nitrocellulose filter binding assay (24) was employed to
detect factors that specifically bind to polyoma Pvu II
fragment 4 (nt 5128-5262, Fig. 1) from the wt and the F9 hrN2
mutant. The Pvu II fragment 4 contains enhancer elements B,
C, and E (Fig. 1). Region E is altered by point mutation
(adenosine to guanosine transition at nt 5230) and subsequent
duplication (nt 5214-5246) in the hrN2 mutant (18). Extracts
contained proteins eluted from nuclei using 0.3 M NaCl.
The results of a filter binding assay using a nuclear extract
from undifferentiated F9 cells is shown in Fig. 2. Binding of
a pBR322 control fragment occurred in the absence of
competitor DNA but was eliminated with increasing concen-
trations of competitor in the reaction. Similar results were
obtained with other control fragments (data not shown). In
contrast, binding of the wt or hrN2 Pvu II fragments 4 was
observed even at high concentrations of competitor DNA.
Similar titrations using nuclear extracts from differentiated
F9 cells and human HeLa cells (Fig. 2) as well as mouse L
cells (data not shown) also demonstrated specific binding to
the wt and hrN2 Pvu II fragments 4. Titration experiments
also were performed using increasing concentrations of
nuclear extract in the binding assay with a fixed concentra-
tion of competitor DNA. With increasing concentrations of
extract, binding of pBR322 DNA varied marginally above
background while specific binding of the wt or hrN2 Pvu II
fragment 4 increased to saturation (data not shown).
We used DNase I footprint analysis to define the binding
site(s) for the factor(s) interacting with the polyoma enhancer
fragments. Conditions for binding at saturation were used
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FIG. 2. Titration of competitor DNA in the filter binding assay.
pBR, EcoRI-EcoRV fragment of pBR322 used as nonspecific DNA;
host range (hr), Pvu II fragment 4 from F9 mutant hrN2; wt, Pvu II
fragment 4 of wt polyoma virus. Binding reactions were performed
as described in the text, filtered through nitrocellulose, and exposed
to film for autoradiography. The 50-.ul binding reactions contained
0.65 jug of protein (nuclear extract), 2000 cpm of labeled DNA, and
various concentrations of competitor DNA. Lanes 1-9 contained the
following concentrations of competitor DNA in binding assays using
nuclear extracts prepared from undifferentiated F9 cells. Lanes: 1, 0
Ag; 2, 0.0105 jig; 3, 0.0158 tg; 4, 0.0268 ug; 5, 0.0525 jug; 6, 0.105 jig;
7, 0.158 ,ug; 8, 0.263 ug; 9, 0.525 Atg. The binding reactions in lanes
10 and 11 utilized nuclear extracts prepared from differentiated F9
cells and human HeLa cells, respectively. Lane 10, 3.5,g of protein,
6000 cpm of labeled DNA, and 1.05 ,4g of competitor DNA. Lane 12,
0.6 ug of protein, 2000 cpm of labeled DNA, and 0.105 tkg of
competitor DNA.
followed by DNase I digestion to give single nuclease cuts per
molecule. As shown in Fig. 3, identical regions of protection
were detected with the wt polyoma and hrN2 fragments using
nuclear extracts from undifferentiated F9 cells. The footprint
is located between nt 5155 and 5174. An identical region of
protection was obtained using wt and hrN2 fragments labeled
at the opposite end (nt 5262) with 32p (data not shown). Using
these conditions, no protection was detected in either the wt
or hrN2 fragments corresponding to enhancer elements B or
E. Footprint analyses also were performed using nuclear
extracts from differentiated F9 cells and human HeLa cells
(Fig. 4). The same region of protection (nt 5155-5174) again
was observed with Pvu II fragment 4 from the hrN2 (Fig. 4)
and wt (data not shown).
The polyoma nucleotide sequence around the region of the
footprint is shown in Fig. 5. A 6-bp inverted repeat is located
precisely within the boundaries of the region of nuclease
protection. The repeated sequences (5' AGTTGC 3') are
separated by 3 bp. A single copy of this sequence is located
on the early side of the polyoma origin ofDNA replication (nt
63-68, Fig. 1). We tested whether this sequence was capable
ofbinding the factor using the filter binding assay. A fragment
spanning this region (nt 5262-162, Fig. 1) was used with
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FIG. 3. DNase I footprint analyses of Pvu II fragment 4 from wt
and hrN2 using nuclear extracts prepared from undifferentiated F9
cells. wt and hrN2 (hr) fragments were 32P-labeled adjacent to the
Pvu II site at polyoma nt 5128. Lanes 1-4 are ladders obtained when
labeled DNAs were treated with DNase I without previous incuba-
tion with nuclear extract. Lanes 5-8 are ladders obtained when
labeled DNAs were treated with DNase I after incubation with
nuclear extract (31 ,g of protein). The 250-,ul reaction mixtures
contained 5.25 ,ug of competitor DNA and 30,000 cpm of labeled
DNAs. Concentrations of DNase I were as follows. Lanes: 1, 0.012
unit/ml; 2, 0.024 unit/ml; 3, 0.048 unit/ml; 4, 0.24 unit/ml; 5, 1.2
unit/ml; 6, 0.48 unit/ml; 7, 0.24 unit/ml; 8, 0.048 unit/ml. Lanes G,
GA, CT, and C show homologous sequencing ladders.
erx -
FIG. 4. DNase I footprint analyses of the hrN2 Pvu II fragment
4 using nuclear extracts prepared from HeLa cells and differentiated
F9 cells. The hrN2 fragment was labeled adjacent to the Pvu II site
at polyoma nt 5128. For HeLa cell extracts, 250-/.d reaction mixtures
contained 5.3 jig of competitor DNA, 32.5 ;.tg of protein, and 30,000
cpm of labeled DNA. For differentiated F9 cell extracts, 250-/41
reaction mixtures contained 5.3 jig of competitor DNA, 32.8 jig of
protein, and 30,000 cpm of labeled DNA. Lanes 1-3 are ladders
obtained when labeled DNAs were digested with DNase I after
incubation with nuclear extract. Lanes 4-6 are ladders obtained
when labeled DNAs were digested with DNase I without prior
incubation with nuclear extract. Concentrations of DNase I were as
follows. Lanes: 1, 1.2 unit/ml; 2, 0.48 unit/mi; 3, 0.24 unit/ml; 4,
0.048 unit/ml; 5, 0.024 unit/ml; 6, 0.012 unit/ml. Homologous
sequencing ladders are shown.
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FIG. 5. Nucleotide sequence of the region around the EF-C footprint and structure of the pUC-EFC plasmid clone. Polyoma (Py) nt
5150-5178 were cloned into pUC9. The pUC and polyoma sequence boundaries are indicated as are relevant restriction nuclease sites. The region
of nuclease protection due to bound EF-C (nt 5155-5174) is indicated by the bar above the sequence. The inverted repeat described in the text
(5' AGTTGC 3') is indicated by arrows.
nuclear extracts from undifferentiated F9 cells and HeLa
cells under a variety of binding conditions. No specific
binding to this region was detected in assays containing KCl
concentrations from 5 mM to 100 mM and containing protein
(extract) concentrations from 1 ,ug to 25 ,ug per 50 ,ul assay
(data not shown).
To test whether sequences outside the footprint are re-
quired for binding, a plasmid (pUC-EFC) was constructed
that contains polyoma nt 5150-5178 inserted in pUC9 (Fig. 5).
The polyoma sequences in this plasmid contain the region of
nuclease protection (nt 5155-5174) plus only 5 bp upstream
and 4 bp downstream from this region. This fragment was
excised from the vector using restriction sites that flank the
polyoma sequences (Fig. 5, HindIII and EcoRI) and leave 31
bp upstream and 15 bp downstream from the protected
region. Specific binding of this fragment was detected using
nuclear extracts from undifferentiated F9 cells under condi-
tions that were identical to those established for binding to
the entire Pvu II fragment 4 region (data not shown). DNase
I footprint analysis demonstrated that an identical region of
protection was obtained with this fragment as with Pvu II
fragment 4 from wt polyoma and hrN2 (Fig. 6).
DISCUSSION
We have identified a nuclear factor that specifically binds to
the polyomavirus enhancer region. This factor is present in
nuclear extracts prepared from undifferentiated and differ-
entiated F9 murine embryonal carcinoma cells as well as
differentiated murine L and human HeLa cells. The binding
activity in each of these extracts is similar, suggesting that
expression of this factor is not regulated by the state of cell
differentiation. The fact that this factor is found in mouse and
human cells is not surprising since the polyoma enhancer
region functions in both cell types (31). The region of
nuclease protection detected after factor binding spans 20 bp
and is located between nt 5155 and 5174. Our results
demonstrate that these sequences, and at most 5 bp upstream
and 4 bp downstream from this region, contain an intact
binding domain. Because of the nature of the assay used in
these studies, binding of DNA-protein complexes to nitro-
cellulose, we suggest that this factor is a protein. Under the
conditions used for preparation of nuclear extracts and in
vitro binding assays, we have not detected other factors that
interact with the polyoma Pvu II fragment 4.
The region of nuclease protection conferred by factor
binding (nt 5155-5174) corresponds precisely to enhancer
element C (nt 5148-5179, Fig. 1) defined by the genetic
analyses of Veldman et al. (14). This region is required for
efficient polyoma DNA replication in vivo (7, 14). Enhancer
element C in conjunction with element A (the ElA enhancer
homology, Fig. 1) represent the predominant enhancer ele-
ments in the polyoma enhancer region that are required for
viral DNA replication (14). Specific deletion of these two
elements (deletion of nt 5101-5165) abolishes replication
enhancer function of the entire enhancer region (nt 5021-
5262; ref. 14). Enhancer element C also regulates transcrip-
tion ofboth the early and late regions of the polyoma genome
(7, 22). We define the factor that interacts with this region as
EF-C, enhancer binding factor to polyoma element C.
The boundaries of the EF-C binding domain also correlate
with the ( regulatory region (nt 5157-5181) defined by
Maione et al. (32). The integrity of this region is maintained
in. all viable polyoma host range mutants that have been
isolated on various undifferentiated murine cell lines. These
mutants contain a variety of genetic alterations in the
polyoma enhancer region (nt 5021-5262) that include point
mutations, deletions, insertions, and rearrangements. It ap-
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FIG. 6. DNase I footprint analysis of a minimal EF-C binding
domain using nuclear extracts prepared from undifferentiated F9
cells. The pUC-EFC clone shown in Fig. 5 was 32P-labeled at the
HindII site, and the HindIII-EcoRI fragment was used for nuclease
footprint analysis following a standard binding reaction. The 250-,ul
reaction mixtures contained 7.5 ,ug of competitor DNA, 85 ,ug of
protein, and 30,000 cpm of labeled DNA. Lanes 1-3 are ladders
obtained when labeled DNAs were digested with DNase I without
prior incubation with nuclear extract. Lanes 4-6 are ladders obtained
when labeled DNAs were digested with DNase I after incubation
with nuclear extract. Concentrations of DNase I were as follows.
Lanes: 1, 0.012 unit/ml; 2, 0.024 unit/ml; 3, 0.048 unit/ml; 4, 0.24
unit/ml; 5, 0.48 unit/ml; 6, 1.2 unit/ml. A homologous sequencing
ladder is shown. The bar adjacent to the footprint corresponds to the
bar above the sequence in Fig. 5.
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pears likely that enhancer element C defined by Veldman et
al. (14) and the fi regulatory region defined by Maione et al.
(32) are equivalent and that the function of this region is
mediated by EF-C binding.
A 6-bp inverted repeat, separated by 3 bp, is contained
symmetrically within the boundaries ofthe region ofnuclease
protection conferred by EF-C binding. The EF-C protein,
therefore, may bind as a dimer. Two lines ofevidence support
this possibility. First, a number of DNase I hypersensitive
cleavage sites were observed that are located outside the
footprint (for example, see Fig. 3). While the intensity of
these sites varied from experiment to experiment, the same
DNase I hypersensitive cleavage sites were consistently
observed and map to nucleotides that are 6, 9, and 11 bp on
the 5' side of the upstream repeat and 7, 10, and 12 bp on the
3' side of the downstream repeat. Thus, hypersensitive sites
induced by EF-C binding symmetrically flank the inverted
repeat sequence. Second, a single copy of the repeated
sequence located on the early side ofthe polyoma replication
origin did not detectably bind EF-C. Thus we speculate that
EF-C binding is stabilized by dimerization.
Several other groups have defined nuclear factors that
interact with the polyoma Pvu II fragment 4. The factor
described by Fujimura (33) binds to a region that precisely
corresponds to the EF-C binding domain and these two
factors are undoubtedly the same. Nuclear factors identified
by Piette et al. (34) and Bohnlein and Gruss (35) also bind to
the Pvu II fragment 4. The predominant binding activity
observed by these authors corresponds to element B of the
enhancer region (Fig. 1). This region is immediately adjacent
to the EF-C binding domain. It will be interesting to deter-
mine whether the factors that bind these two elements
interact with each other.
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